Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer

Allal, Abdelkarim Said; Zwahlen, Daniel; Becker, Minerva; Dulguerov, Pavel; Mach, Nicolas

Scientific article

Open access

English

Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer

ContributorsAllal, Abdelkarim Said; Zwahlen, Daniel; Becker, Minerva; Dulguerov, Pavel; Mach, Nicolas

Published inThe cancer journal, vol. 12, no. 1, p. 63-68

Publication date2006

Abstract

This study was conducted to determine the maximum tolerated dose of docetaxel when administered concomitantly with radical hyperfractionated radiotherapy and cisplatin in patients with locally advanced head and neck cancer.

Keywords

Aged
Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects
Carcinoma, Squamous Cell/pathology/therapy
Cisplatin/administration & dosage/adverse effects
Combined Modality Therapy
Deglutition Disorders/etiology
Dose Fractionation
Dose-Response Relationship, Drug
Female
Head and Neck Neoplasms/pathology/therapy
Humans
Male
Maximum Tolerated Dose
Middle Aged
Mucositis/etiology
Neck Dissection
Neoplasm Staging
Taxoids/administration & dosage/adverse effects
Treatment Outcome

Affiliation

Research group

Citation (ISO format)

ALLAL, Abdelkarim Said et al. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer. In: The cancer journal, 2006, vol. 12, n° 1, p. 63–68.

Article (Published version)

Identifiers

PID : unige:33098
PMID : 16613664

ISSN of the journal1528-9117

617views

465downloads

Creation10/28/2013 8:08:00 PM

First validation10/28/2013 8:08:00 PM

Update time03/14/2023 8:50:04 PM

Status update03/14/2023 8:50:04 PM

Last indexation01/16/2024 1:53:55 PM

Archive ouverte UNIGE

Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer

This study was conducted to determine the maximum tolerated dose of docetaxel when administered concomitantly with radical hyperfractionated radiotherapy and cisplatin in patients with locally advanced head and neck cancer.

Technical informations